Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study
- 27 March 2015
- journal article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 47 (5) , 823-829
Abstract
Varenicline is a new most effective drug for smoking cessation. Its effect on kidney functions remains unclear. This study purposed to investigate whether varenicline causes nephrotoxicity in rats. Fifteen rats were randomly assigned to three groups: control, 0.0125 mg kg−1 varenicline and 0.025 mg kg−1 varenicline (single dose for 3 days, i.p.). Before and after experimental period, serum neutrophil gelatinase-associated lipocalin, creatinine and urea levels were measured. Total oxidant and antioxidant status were measured in kidney homogenates. Histological examination was performed in kidney. The nephrotoxic effects of varenicline were detected by histopathological and biochemical examinations in the varenicline treatment groups. No change was observed in the control group. These findings firstly indicate that a 3-day varenicline treatment causes nephrotoxic effects in rats.Keywords
This publication has 29 references indexed in Scilit:
- Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritisBMC Nephrology, 2013
- Acute kidney injuryThe Lancet, 2012
- Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysisCanadian Medical Association Journal, 2011
- Single- and Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Japanese Adult SmokersThe Journal of Clinical Pharmacology, 2011
- Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trialBMJ, 2010
- Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineDrug Safety, 2010
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009
- Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injuryNephrology Dialysis Transplantation, 2008
- Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and NonsmokersThe Journal of Clinical Pharmacology, 2006
- METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRODrug Metabolism and Disposition, 2006